News 2012
Below you find a list of all LEO Pharma press releases from 2012. The press releases are only intended for use by journalists.
Press releases
14-05-2012
LEO Pharma Korea marks first anniversary by helping treat skin disease in children
LEO Pharma Korea announces new funds to treat skin disease in children in Korea. The Danish Crown Prince Couple were present at the donation ceremony, which coincides with LEO Pharma Korea’s first anniversary.
18-04-2012
LEO Pharma embarks on a journey to become a truly global and patient-centric organisation
LEO Pharma has embarked on the next step in its growth strategy: to build a truly global and patient-centric organisation.
27-03-2012
Performance in line with growth strategy
2011 was a successful year for LEO Pharma despite the global economic downturn, with double-digit sales growth in dermatology, continued growth in the US and a strengthened pipeline. The company's achievements are in line with its ambitious growth strategy.
24-02-2012
New Executive Vice President at LEO Pharma
On 1 March 2012, Anders B. Spohr takes over the position as Executive Vice President for Global Product Supply at LEO Pharma
26-01-2012
LEO Pharma announces that Picato® (ingenol mebutate) gel has been approved by US FDA for once-daily, 2 or 3 day treatment of actinic keratoses
LEO Pharma today announced that Picato® (ingenol mebutate) gel (0.015%, 0.05%) has been approved by the US Food and Drug Administration (FDA) as a treatment for actinic keratoses (AK) on the face, scalp, trunk and extremities.
11-01-2012
Life science students receive LEO Pharma innovation award
This month LEO Pharma presented its BioBusiness & Innovation Program (BBIP) business plan award to a group of innovative, Danish life science students. During the ceremony, it was also announced that BBIP’s new master degree in BioBusiness Entrepreneurship - co-founded and co-sponsored by LEO Pharma and other life-science companies - will start in September 2012.
09-01-2012
LEO Pharma A/S in-licenses promising compound from Virobay Inc. for oral treatment of psoriasis
LEO Pharma A/S, a global pharmaceutical company specializing in dermatology, has entered into a multi-million dollar collaboration with the US biotech company Virobay Inc. to develop an oral treatment for psoriasis.
